Breast Cancer Topo ¢ò ¦Á Expression In The Basic Law And Related Research, And The Efficacy Of Anthracyclines

Breast cancer is the most common malignant disease of women. The mortality for breast cancer is the highest one in female,and being rise these years.It is a traditional topic to search the prognostic marker relevant to breast cancer treatment. Anthracycline is one of the most effective drug in breast cancer treatment,it can improve the patient's therapeutic efficacy and overall survival.For the local efficacy and the adverse of anthracycline ,and to avoid over treatment,search an ideal molecular biologic marker that has predictive value for anthracycline is very necessary. The DNA topoisomerase IIα(topo IIα) is the effective target of many antitumor medicine including anthracycline.It is often associated with drug resistance when its level decrease.Our study considering the biological behaviour direct the breat cancer prognosis and treatment ,study the regular pattern of topo IIαexpression in breast cancer,analyze the correlation of topo IIαand anthracycline effect.Collecting clinical data of advanced patients who had received anthracycline in our department for analyze retrospectively. Tested 180 cases by immunohistochem istry(IHC) staining and judged the result by microscopic scoring. Compare the relationship between topo IIαexpression and anthracycline effect and clinicopathological marker by statistics analyze.First part:we analyzed the regularity of topo IIαexpression in breast cancer. The relatede biomarkers and topo IIαwere tested by immunohistochemical (IHC) procedures in operational paraffin-embedded tumor blocks and material tissue paraffin-embedded tumor blocks. The results showed that a high topo IIαpositive rate (52.2%)was significantly present in breast cancer. We found topo IIαexpression in breast cancer was not associated with any of the clinicopathological parameters such as age , menstruation status, histologic type, clinical TNM stage and metastasis site(P> 0.05),while it was associated with tumor size, axillary lymphonodus metastasis and metastasis site numbers(P<0.05). With regard to the other important biomarkers ,We didn't found the correlation between ER,PR and the expression of topo IIα(P>0.05),but our study show the correlation with HER-2 (P<0.05) ,and HER-2 is coexpressed with topo IIα.We also analyzed some other biomarkers,as P53,MDR-1,Bcl—2,PCNA,but the statistics result show they are not associated with topo IIα(P>0.05).Second part:our study emphasized on the relationship between the clinical response to anthracycline and topo IIαin metastatic or locally advanced breast cancer patients.The result show the positive expression of topo IIαhad significant relativity with the clinical response of anthracycline and TTP(P<0.05).In addition,our study found topo IIαexpression have no correlation with disease-free survival (DFS) and overall survival (OS).